116 related articles for article (PubMed ID: 38537990)
1. Surgical Resection of Primary Tumor for Bone Metastatic Breast Cancer Patients at Initial Presentation.
Kitsuya N; Matsuoka M; Onodera T; Yokota I; Iwasaki K; Suzuki Y; Hamasaki M; Kondo E; Iwasaki N
Anticancer Res; 2024 Apr; 44(4):1591-1601. PubMed ID: 38537990
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome.
Lobbezoo DJ; van Kampen RJ; Voogd AC; Dercksen MW; van den Berkmortel F; Smilde TJ; van de Wouw AJ; Peters FP; van Riel JM; Peters NA; de Boer M; Borm GF; Tjan-Heijnen VC
Breast Cancer Res Treat; 2013 Oct; 141(3):507-14. PubMed ID: 24104881
[TBL] [Abstract][Full Text] [Related]
4. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
6. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
Malmgren J; Hurlbert M; Atwood M; Kaplan HG
Breast Cancer Res Treat; 2019 Apr; 174(2):505-514. PubMed ID: 30560462
[TBL] [Abstract][Full Text] [Related]
7. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
8. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990-2010.
Malmgren JA; Mayer M; Atwood MK; Kaplan HG
Breast Cancer Res Treat; 2018 Jan; 167(2):579-590. PubMed ID: 29039120
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
11. De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype.
Press DJ; Miller ME; Liederbach E; Yao K; Huo D
Clin Exp Metastasis; 2017 Dec; 34(8):457-465. PubMed ID: 29288366
[TBL] [Abstract][Full Text] [Related]
12. Impact of Subtype on Survival of Young Patients With Stage IV Breast Cancer.
Ogiya R; Sagara Y; Niikura N; Freedman RA
Clin Breast Cancer; 2019 Jun; 19(3):200-207.e1. PubMed ID: 30795886
[TBL] [Abstract][Full Text] [Related]
13. Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.
Tao L; Chu L; Wang LI; Moy L; Brammer M; Song C; Green M; Kurian AW; Gomez SL; Clarke CA
Cancer Causes Control; 2016 Sep; 27(9):1127-38. PubMed ID: 27496200
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study.
Leone JP; Leone J; Zwenger AO; Vallejo CT; Leone BA
Am J Clin Oncol; 2019 Jul; 42(7):588-595. PubMed ID: 31166208
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
17. Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis.
Gong Y; Zhang J; Ji P; Ling H; Hu X; Shao ZM
Cancer Med; 2018 Aug; 7(8):4156-4169. PubMed ID: 29984914
[TBL] [Abstract][Full Text] [Related]
18. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
19. Survival differences between HER2-0 and HER2-low-expressing breast cancer - A meta-analysis of early breast cancer patients.
Yang C; Zhang X; Chen Y; Li P; Zhang J; Xu A; Huang N; Liang M; Chen Y; Wang K
Crit Rev Oncol Hematol; 2023 May; 185():103962. PubMed ID: 36921780
[TBL] [Abstract][Full Text] [Related]
20. Survival is associated with repressive histone trimethylation markers in both HR-positive HER2-negative and triple-negative breast cancer patients.
Wang B; Zhou M; Shi YY; Chen XL; Ren YX; Yang YZ; Tang LY; Ren ZF
Virchows Arch; 2023 Jun; 482(6):1047-1056. PubMed ID: 37059917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]